Fig. 5: Met and SPRY2 are required for increased metastatic potential and clonogenic capacity in RMS cells. | Cell Death & Disease

Fig. 5: Met and SPRY2 are required for increased metastatic potential and clonogenic capacity in RMS cells.

From: SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma

Fig. 5

Representative images of MET, SPRY2 and control siRNA treated RD (a) and SJRH30 (g) cells allowed to migrate for 24-h in transwell migration assays are shown. Migration calculated as percentage relative to control siRNA transfected RD (b) and SJRH30 (h) cells was significantly reduced in MET or SPRY2 silenced cells. To assess the effect of MET or SPRY2 silencing on anchorage-independent colony formation, soft agar assay was performed with RD (c) and SJRH30 (i) cells PsiRT, culturing the cells for about 2-weeks. The number of colonies formed by MET or SPRY2 silenced RD cells was significantly reduced (d) but was not affected in the case of SJRH30 cells (j). Anchorage-dependent clonogenic assay was performed by culturing MET, SPRY2 or control siRNA transfected RMS cells for 8 days and staining the colonies with crystal violet (e, k). Representative images of wells and single colonies of MET, SPRY2 or control transfected RD (e, e′) and SJRH30 (k, k′) cells are shown. Colony formation was inhibited significantly in MET or SPRY2 silenced RD (f) and SJRH30 (l) cells compared to control siRNA transfected cells. The graphical data represent the mean ± SEM of a minimum of three independent experiments. Scale bar in panels a, g, e′ and k′ is 100 µm, and is 800 µm in (c) and (i)

Back to article page